Trends in nano-antimicrobial therapy for severe liver disease with infection

Zhenqun LUO; Xinhua LUO

doi:10.3969/j.issn.1001-5256.2023.03.036

Volume 39 Issue 3

Mar. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(3): 713-717

PDF( 1748 KB)

Trends in nano-antimicrobial therapy for severe liver disease with infection

DOI: 10.3969/j.issn.1001-5256.2023.03.036

Zhenqun LUO^{1, 2},
Xinhua LUO^{2
,
,
,}

1.
School of Clinical Medicine, Zunyi Medical University, Zunyi, Guizhou 563000, China
2.
Department of Infectious Diseases, Guizhou Provincial People's Hospital, Guiyang 550000, China

More Information

Corresponding author: LUO Xinhua, luoxh09@163.com (ORCID: 0000-0002-0323-3868)
Received Date: 2022-07-19
Accepted Date: 2022-09-09
Published Date: 2023-03-20

Abstract

Abstract

Severe liver disease with infection has always been a key and difficult point in clinical treatment. Through continuous exploration of nanomaterials, researchers have found that nanomaterials can achieve targeted antibacterial and immunomodulatory effects due to their special physicochemical properties. With reference to recent articles and advances, this article reviews the possible mechanisms of nano-therapies for severe liver disease with infection from the aspects of targeted antibacterial effect of nanomaterials without antibiotics, targeted antibacterial effect of nano-drug delivery systems, and targeted immunomodulatory therapy, so as to provide new treatment strategies for the prevention and treatment of severe liver disease with infection in clinical practice.
- Liver Diseases,
- Infection,
- Nanoparticles

FullText(HTML)

References(31)

References

[1]	CASULLERAS M, ZHANG IW, LÓPEZ-VICARIO C, et al. Leukocytes, systemic inflammation and immunopathology in acute-on-chronic liver failure[J]. Cells, 2020, 9(12): 2632. DOI: 10.3390/cells9122632.
[2]	ALBILLOS A, MARTIN-MATEOS R, van der MERWE S, et al. Cirrhosis-associated immune dysfunction[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(2): 112-134. DOI: 10.1038/s41575-021-00520-7.
[3]	ALBILLOS A, de GOTTARDI A, RESCIGNO M. The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577. DOI: 10.1016/j.jhep.2019.10.003.
[4]	FERNÁNDEZ J, ACEVEDO J, WIEST R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis[J]. Gut, 2018, 67(10): 1870-1880. DOI: 10.1136/gutjnl-2017-314240.
[5]	PIANO S, SINGH V, CARACENI P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide[J]. Gastroenterology, 2019, 156(5): 1368-1380. e10. DOI: 10.1053/j.gastro.2018.12.005.
[6]	CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.
[7]	Society of Infectious Diseases, Chinese Medical Association. Expert consensus on diagnosis and treatment of end-stage liver disease complicated infection (2021 version)[J]. Clin Hepatol, 2022, 38(2): 304-310. DOI: 10.3760/cma.j.cn501113-20220209-00061. 中华医学会感染病学分会. 终末期肝病合并感染诊治专家共识(2021年版)[J]. 临床肝胆病杂志, 2022, 38(2): 304-310. DOI: 10.3760/cma.j.cn501113-20220209-00061.
[8]	BARENHOLZ Y. Doxil^®--the first FDA-approved nano-drug: lessons learned[J]. J Control Release, 2012, 160(2): 117-134. DOI: 10.1016/j.jconrel.2012.03.020.
[9]	SHAH S, DHAWAN V, HOLM R, et al. Liposomes: Advancements and innovation in the manufacturing process[J]. Adv Drug Deliv Rev, 2020, 154-155: 102-122. DOI: 10.1016/j.addr.2020.07.002.
[10]	FDA. Accelerated approval lpad pathway approval[EB/OL]. [2018-09-28]. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/207356Orig1s000ltr.pdf.
[11]	GUPTA A, MUMTAZ S, LI CH, et al. Combatting antibiotic-resistant bacteria using nanomaterials[J]. Chem Soc Rev, 2019, 48(2): 415-427. DOI: 10.1039/c7cs00748e.
[12]	RIDUAN SN, ZHANG Y. Nanostructured Surfaces with multimodal antimicrobial action[J]. Acc Chem Res, 2021, 54(24): 4508-4517. DOI: 10.1021/acs.accounts.1c00542.
[13]	LINKLATER DP, BAULIN VA, LE GUÉVEL X, et al. Antibacterial action of nanoparticles by lethal stretching of bacterial cell membranes[J]. Adv Mater, 2020, 32(52): e2005679. DOI: 10.1002/adma.202005679.
[14]	WU R, OU X, TIAN R, et al. Membrane destruction and phospholipid extraction by using two-dimensional MoS2 nanosheets[J]. Nanoscale, 2018, 10(43): 20162-20170. DOI: 10.1039/c8nr04207a.
[15]	SHARMA D, MISBA L, KHAN AU. Antibiotics versus biofilm: an emerging battleground in microbial communities[J]. Antimicrob Resist Infect Control, 2019, 8: 76. DOI: 10.1186/s13756-019-0533-3.
[16]	BI X, BAI Q, LIANG M, et al. Silver peroxide nanoparticles for combined antibacterial sonodynamic and photothermal therapy[J]. Small, 2022, 18(2): e2104160. DOI: 10.1002/smll.202104160.
[17]	DING L, JIANG J, CHENG L, et al. Oral administration of nanoiron sulfide supernatant for the treatment of gallbladder stones with chronic cholecystitis[J]. ACS Appl Bio Mater, 2021, 4(5): 3773-3785. DOI: 10.1021/acsabm.0c01258.
[18]	LI J, MENG Z, ZHUANG Z, et al. Effective therapy of drug-resistant bacterial infection by killing planktonic bacteria and destructing biofilms with cationic photosensitizer based on phosphindole oxide[J]. Small, 2022, 18(17): e2200743. DOI: 10.1002/smll.202200743.
[19]	BOCATE KP, REIS GF, de SOUZA PC, et al. Antifungal activity of silver nanoparticles and simvastatin against toxigenic species of Aspergillus[J]. Int J Food Microbiol, 2019, 291: 79-86. DOI: 10.1016/j.ijfoodmicro.2018.11.012.
[20]	ZHOU H, TANG D, KANG X, et al. Degradable pseudo conjugated polymer nanoparticles with NIR-Ⅱ photothermal effect and cationic quaternary phosphonium structural bacteriostasis for anti-infection therapy[J]. Adv Sci (Weinh), 2022, 9(16): e2200732. DOI: 10.1002/advs.202200732.
[21]	GAO F, SHAO T, YU Y, et al. Surface-bound reactive oxygen species generating nanozymes for selective antibacterial action[J]. Nat Commun, 2021, 12(1): 745. DOI: 10.1038/s41467-021-20965-3.
[22]	AHAMAD N, KAR A, MEHTA S, et al. Immunomodulatory nanosystems for treating inflammatory diseases[J]. Biomaterials, 2021, 274: 120875. DOI: 10.1016/j.biomaterials.2021.120875.
[23]	MA Q, FAN Q, XU J, et al. Calming cytokine storm in pneumonia by targeted delivery of TPCA-1 using platelet-derived extracellular vesicles[J]. Matter, 2020, 3(1): 287-301. DOI: 10.1016/j.matt.2020.05.017.
[24]	XI J, AN L, HUANG Y, et al. Ultrasmall FeS2 nanoparticles-decorated carbon spheres with laser-mediated ferrous ion release for antibacterial therapy[J]. Small, 2021, 17(13): e2005473. DOI: 10.1002/smll.202005473.
[25]	FENG X, XU W, LI Z, et al. Immunomodulatory nanosystems[J]. Adv Sci (Weinh), 2019, 6(17): 1900101. DOI: 10.1002/advs.201900101.
[26]	QU X, WANG M, WANG M, et al. Multi-mode antibacterial strategies enabled by gene-transfection and immunomodulatory nanoparticles in 3D-printed scaffolds for synergistic exogenous and endogenous treatment of infections[J]. Adv Mater, 2022, 34(18): e2200096. DOI: 10.1002/adma.202200096.
[27]	YE M, ZHAO Y, WANG Y, et al. PH-responsive polymer-drug conjugate: an effective strategy to combat the antimicrobial resistance[J]. Adv Funct Mater, 2020, 30(39): 2002655. DOI: 10.1002/adfm.202002655.
[28]	MIRVAKILI SM, NGO QP, LANGER R. Polymer nanocomposite microactuators for on-demand chemical release via high-frequency magnetic field excitation[J]. Nano Lett, 2020, 20(7): 4816-4822. DOI: 10.1021/acs.nanolett.0c00648.
[29]	SOTO F, WANG J, AHMED R, et al. Medical micro/nanorobots in precision medicine[J]. Adv Sci (Weinh), 2020, 7(21): 2002203. DOI: 10.1002/advs.202002203.
[30]	ARQUÉ X, TORRES M, PATIÑO T, et al. Autonomous treatment of bacterial infections in vivo using antimicrobial micro- and nanomotors[J]. ACS Nano, 2022, 16(5): 7547-7558. DOI: 10.1021/acsnano.1c11013.
[31]	MAŤÁTKOVÁ O, MICHAILIDU J, MIŠKOVSKÁ A, et al. Antimicrobial properties and applications of metal nanoparticles biosynthesized by green methods[J]. Biotechnol Adv, 2022, 58: 107905. DOI: 10.1016/j.biotechadv.2022.107905.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (431) PDF downloads(74)

Trends in nano-antimicrobial therapy for severe liver disease with infection

DOI: 10.3969/j.issn.1001-5256.2023.03.036

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Trends in nano-antimicrobial therapy for severe liver disease with infection

DOI: 10.3969/j.issn.1001-5256.2023.03.036

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content